| 0.7576 0.02 (2.74%) | 08-11 12:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1 | 1-year : | 1.1 |
| Resists | First : | 0.86 | Second : | 0.94 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.72 | Second : | 0.59 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.77 |
| MA(100) : | 0.76 |
MA(250) : | 0.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18 |
D(3) : | 16 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 2.34 | Low : | 0.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TNYA ] has closed below upper band by 46.5%. Bollinger Bands are 64.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.76 |
| Low: | 0.72 - 0.73 | 0.73 - 0.73 |
| Close: | 0.73 - 0.74 | 0.74 - 0.74 |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Tue, 11 Aug 2026
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mon, 10 Aug 2026
Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA - MarketBeat
Wed, 05 Aug 2026
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Tue, 04 Aug 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - GlobeNewswire
Tue, 04 Aug 2026
Tenaya CFO Eric Hyllengren to Speak at Boston Conference - Stock Titan
Sat, 25 Jul 2026
Tenaya Therapeutics, Inc. Revenue Breakdown – NASDAQ:TNYA - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 224 (M) |
| Held by Insiders | 2.1607e+008 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 28,660 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.832e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 917.7 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 225000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -26.38 |
| EBITDA (p.s.) | 80645.2 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 4.3 |
| Dividend | 0 |
| Forward Dividend | 2.492e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|